{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:04:30Z","timestamp":1784127870099,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Gastric and colorectal cancers present significant therapeutic challenges, particularly in the elderly population, who often have comorbidities and diminished tolerance to standard treatments. This report describes an 85-year-old male with concurrent stage III gastric adenocarcinoma and stage IIIb microsatellite stable colorectal cancer, who declined both surgery and chemotherapy. Subsequently, the patient was treated with an innovative regimen consisting of endoscopic intratumoral injections of Oncolytic adenovirus H101 in combination with the PD-1 inhibitor tislelizumab. Following this combined therapeutic approach, the patient demonstrated notable tumor shrinkage and downstaging, accompanied by a reduction in serum tumor markers, including CEA and CA19-9. Additionally, there was an observed increase in CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell counts, indicating systemic immune activation. The treatment was well-tolerated, with the only reported adverse event being mild fever. The patient achieved nearly 4 months of progression-free survival and a substantial improvement in quality of life. This case highlights the potential of combining oncolytic virotherapy with PD-1 inhibition as a promising and novel personalized strategy for treating elderly patients with advanced gastrointestinal cancers who are unsuitable candidates for conventional therapies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1719438","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:28:40Z","timestamp":1763706520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Local and systemic combination therapy: endoscopic injection of an oncolytic virus with PD-1 inhibitor for an elderly patient with advanced gastrointestinal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Siqi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangren","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-023-00987-4","article-title":"Prognosis of elderly patients with gastric cancer treated with the best supportive care","volume":"55","author":"Kubo","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jgs.18096","article-title":"What matters most?\u201d for older patients who have cancer","volume":"71","author":"Dos Santos Hughes","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000541","article-title":"Palliative and end-of-life care for the older adult with cancer","volume":"15","author":"Huynh","year":"2021","journal-title":"Curr Opin Sup Palliat Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN Guidelines\u00ae Insights: Older adult oncology, version 1.2021: Featured updates to the NCCN Guidelines","volume":"19","author":"Dotan","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2020.01.006","article-title":"Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab","volume":"11","author":"Ksienski","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2020.01.19.2","article-title":"Colorectal cancer in octogenarian and nonagenarian patients: Clinicopathological features and survivals","volume":"36","author":"Lee","year":"2020","journal-title":"Ann Coloproctol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101980","article-title":"Challenges in the treatment of gastric cancer in the older patient","volume":"85","author":"Joharatnam-Hogan","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1641267","article-title":"Oncolytic viruses in head and neck cancers: Clinical applications and therapeutic potential","volume":"16","author":"Gupta","year":"2025","journal-title":"Front Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1017692","article-title":"Oncolytic virus: A catalyst for the treatment of gastric cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111854","article-title":"Oncolytic viruses as a novel therapeutic approach for colorectal cancer: Mechanisms, current advances, and future directions","volume":"17","author":"P\u00e9rez-Dom\u00ednguez","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70063","article-title":"CDX2 promoter-controlled oncolytic adenovirus suppresses tumor growth and liver metastasis of colorectal cancer","volume":"116","author":"Nakamura","year":"2025","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00807-2","article-title":"The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient","volume":"31","author":"Zhang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"p.3410","DOI":"10.1038\/s41467-023-39156-3","article-title":"Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile","volume":"14","author":"Guo","year":"2023","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9720","article-title":"& Liu, S., Inhibition of colorectal cancer liver metastasis in BALB\/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2498","article-title":"A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer","volume":"31","author":"West","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110478","article-title":"A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors","volume":"200","author":"Barker","year":"2024","journal-title":"Radiother Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.029","article-title":"Oncolytic adenovirus in treating Malignant ascites: A phase II trial and longitudinal single-cell study","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol Ther"},{"key":"B25","first-page":"15","article-title":"\u2018Preliminary study on the efficacy of endoscopic injection of recombinant human type 5 adenovirus combined with chemotherapy for intermediate and advanced esophageal cancer and gastric cancer\u2019","volume":"7","author":"Lyu","year":"2019","journal-title":"J Gen Surg Electr Ed"},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41420-024-02018-y","article-title":"Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1719438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:02Z","timestamp":1763706542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1719438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1719438"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1719438","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1719438"}}